CytoDyn’s Trial for Metastatic Triple-Negative Breast Cancer Demonstrates Safety with 350 mg, 525 mg and 700 mg Dosages; Officially Advances to Phase 2 from Phase 1b

Matthew Durham
Omnidynamic Marketing

Bud Bilanich
Success Coach

Liz Kane
Impactful Strategy

Amy Giles
Increasing Engagement

David Linetsky
Point-of-Care Marketing

Pat Purcell
Meeting Engagement

Stacey Gandler
Brand Nourishment

Brenda Snow
Authentic Patient Voice

Suma Ramadas, PhD
Medical Affairs

Matt Turner
Patient Affordability

Paul Theisen
Patient Acquisition

Frank Burrell
Scientific Storytelling

Joey Cohen
Medication Adherence

Daniel Sontupe
Market Access